PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)

dexamethasone - Generic mfg.

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

WU CART 007 - Wugen

https://library.ehaweb.org/eha/2023/eha2023-congress/386185/kenneth.jacobs.phase.1.2.dose-escalation.study.of.anti-cd7.allogenic.car-t.html?f=menu%3D16%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2489%2Aot_id%3D27911%2Atrend%3D4016%2Amarker%3D4178

Armin Ghobadi; Ibrahim Aldoss; Shannon Maude; Alan S Wayne; Deepa Bhojwani; Ashish Bajel; Bhagirathbhai Dholaria; Rawan Faramand; Ryan Mattison; Michael Rettig; Ouiam Bakkacha; John Muth; Angela Pannunzio; Brett Ramsey; Eileen McNulty; Matthew Cooper; Jan Davidson-Moncada; Kenneth Jacobs; John DiPersio

May 12, 2023